R
R.M. Rifkin
Researcher at Baylor University
Publications - 9
Citations - 636
R.M. Rifkin is an academic researcher from Baylor University. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 5, co-authored 9 publications receiving 602 citations.
Papers
More filters
Journal ArticleDOI
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
Shaji Kumar,Ian W. Flinn,Paul G. Richardson,Parameswaran Hari,Natalie S. Callander,Stephen J. Noga,A. Keith Stewart,Francesco Turturro,R.M. Rifkin,Jeffrey L. Wolf,Jose Estevam,George Mulligan,Hongliang Shi,Iain J. Webb,S. Vincent Rajkumar +14 more
TL;DR: All regimens were highly active and well tolerated in previously untreated MM, and, based on this trial, VDR and VCD-mod are preferred for clinical practice and further comparative testing.
Journal ArticleDOI
Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL.
H. Joachim Deeg,Bruce R. Blazar,Brian J. Bolwell,Gwynn D. Long,Friedrich Schuening,John M. Cunningham,R.M. Rifkin,Sunil Abhyankar,Adrienne D. Briggs,Richard K. Burt,John A. Lipani,Lorin Roskos,J Michael White,Nancy Havrilla,Gisela Schwab,Helen E. Heslop +15 more
TL;DR: In a dose-finding trial, 27 patients with steroid-refractory acute graft-versus-host disease (GVHD) received ABX-CBL, an immunoglobulin M murine monoclonal antibody, recognizes CD147 and initiates cell killing through complement-mediated lysis, and 26 responded, including 13 with complete responses (CR) and 13 with partial responses (PR).
Journal ArticleDOI
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
Shaji Kumar,Ian W. Flinn,Stephen J. Noga,Parameswaran Hari,R.M. Rifkin,Natalie S. Callander,M Bhandari,Jeffrey L. Wolf,Cristina Gasparetto,Amrita Krishnan,D Grosman,Jonathan Glass,Entezam Sahovic,Hongliang Shi,Iain J. Webb,Paul G. Richardson,S V Rajkumar +16 more
TL;DR: The maximum tolerated dose (MTD) of cyclophosphamide in combination with bortezomib, dexamethasone and lenalidomide (VDCR) and VDCR is well tolerated and highly active in untreated multiple myeloma patients.
Journal ArticleDOI
Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study
Shaji Kumar,Ian W. Flinn,Stephen J. Noga,Parameswaran Hari,R.M. Rifkin,Natalie S. Callander,Manish Bhandari,Jeffrey L. Wolf,Cristina Gasparetto,Amrita Krishnan,Daren D Grosman,Jonathan Glass,Entezam Sahovic,Hongliang Shi,Iain J. Webb,Paul G. Richardson,S. Vincent Rajkumar +16 more
TL;DR: Safety and efficacy results from the phase l dose-escalation portion of the study, which sought to determine the maximum tolerated dose (MTD) of the VDCR regimen, represent the first clinical data with this novel 4-drug combination that includes bortezomib, lenalidomide, an alkylator, and a corticosteroid.
Journal ArticleDOI
A Phase III Study Of Enzastaurin In Patients With High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary Treatment: The Prelude Trial
Michael Crump,Sirpa Leppä,Luis Fayad,Je-Jung Lee,Alice Di Rocco,Michinori Ogura,Hans Hagberg,Frederick J. Schnell,R.M. Rifkin,Andreas Mackensen,Fritz Offner,Lauren Pinter-Brown,Sonali M. Smith,Kensei Tobinai,Su-Peng Yeh,Jun Zhu,Marjo Hahka-Kemppinen,Donald Thornton,Peipei Shi,Boris Lin,Brad S. Kahl,Norbert Schmitz,Kerry J. Savage,Thomas M. Habermann +23 more
TL;DR: PRELUDE, a multi-national, randomized, double-blinded, placebo-controlled study, found that enzastaurin did not improve DFS, EFS, or OS in patients with high-risk DLBCL and event-free survival following R-CHOP treatment.